FRANKLIN LAKES, N.J., Sept. 29, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company), a leading global medical technology company, announced today that it received U.S. Food and Drug Administration (FDA) 510(k) clearance for the BD Vacutainer® Barricor™ plasma blood collection tube (BD Barricor), the next generation blood collection and separation technology designed to improve sample quality, help clinicians receive test results faster, and ultimately improve patient care and clinical efficiency.
Continuing BD's longstanding heritage of ensuring best practices in the collection, transportation and processing of blood samples, BD Barricor is a single-use, plastic, evacuated tube used to efficiently obtain high-quality plasma for in vitro diagnostic use. The BD Barricor tube uses a novel mechanical separation technology to obtain plasma from whole blood samples, replacing the need for gel tubes. The BD Barricor tube is the first to leverage this technology in a clinical setting. The revolutionary mechanical separator technology reduces centrifugation time from 10 minutes to three minutes, compared to leading gel tubes, and reduces cellular contamination by 50 to 65 percent compared to leading plasma gel tubes1.
"As we launch BD Barricor tubes in the U.S., we are effectively eliminating the tradeoff of superior sample quality versus quick turnaround often faced by laboratory technicians by providing both a cleaner and faster plasma sample than current methods," said John Ledek, worldwide president of Preanalytical Systems for BD. "This revolutionary technological advancement can improve the accuracy and speed of clinical decision making, and result in enhanced patient care."
The unique advantages of BD Barricor tubes are enabled through an innovative mechanical separation technology which allows the separation of cellular content throughout the centrifugation cycle. As a result, the BD Barricor tube reduces plasma cellular content while also eliminating gel artifacts that can lead to instrument downtime. A cleaner plasma sample improves analyte stability, thereby increasing the window to conduct testing when compared to leading blood separation tubes. Additionally, the mechanical separator is designed not to absorb hydrophobic drugs and can be used as for therapeutic drug testing. As BD Barricor tubes have the potential to reduce manual sample remediation and instrument maintenance, improved laboratory efficiency and lower laboratory costs are also expected.
After receiving FDA 510(k) Clearance, the BD Barricor™ tube is now commercially available. For more information, please visit: http://barricor.bd.com/.
BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures, optimize respiratory care and support the management of diabetes. The company partners with organizations around the world to address some of the most challenging global health issues. BD has more than 45,000 associates across 50 countries who work in close collaboration with customers and partners to help enhance outcomes, lower health care delivery costs, increase efficiencies, improve health care safety and expand access to health. For more information on BD, please visit bd.com.
BD Public Relations
Monique N. Dolecki
BD Investor Relations
1 BD internal data
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bd-receives-fda-510k-clearance-for-innovative-next-generation-blood-collection-and-separation-technology-designed-to-improve-laboratory-efficiency-300335955.html
SOURCE BD (Becton, Dickinson and Company)